Trial Profile
A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutaneous administration of anakinra in patients with cystic fibrosis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Anakinra (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms ANAKIN
- 07 Dec 2022 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.
- 07 Dec 2022 Planned primary completion date changed from 1 Aug 2024 to 1 Dec 2024.
- 07 Dec 2022 Status changed from not yet recruiting to recruiting.